This key milestone establishes CNSide Diagnostics as a Medicare-enrolled clinical laboratory, enabling the submission of claims for its CNSide ® Cerebrospinal Fluid (CSF) Assay Platform, including the ...
Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals ...
Q1 2026 Management View "On today's call, we will review recent progress with our business" and management highlighted a Phase III and launch timeline, with CEO Ian Smith saying Jason Hoitt will ...
Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...
Australia TGA approves Specialised Therapeutics’ Niktimvo for the treatment of chronic graft-versus-host disease: Singapore Tuesday, May 5, 2026, 12:00 Hrs [IST] Independent bio ...
Morning Overview on MSN
Hidden brain waste-removal pathway discovered using MRI — fluid flows along the middle meningeal artery in a lymphatic-like pattern
The human brain has no conventional lymph nodes, no obvious drainage pipes. For most of medical history, scientists assumed ...
Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 -- European Commission ...
Yawning could have an overlooked role in regulating fluids in the brain, according to a groundbreaking new study, which also ...
Independent biopharmaceutical company Specialised Therapeutics is pleased to announce that NIKTIMVO® (axatilimab) has been approved for use in Australia by the Therapeutic Goods Administration (TGA) ...
When this is done well, biomarkers accelerate decision-making, reduce uncertainty, and ultimately bring improved therapies to patients faster. When this is done poorly, however, biomarkers can add ...
Initial Study to Evaluate Entolimod for Gastrointestinal Tissue Preservation in Partial-Body Acute Radiation Syndrome - an Indication for Which No Currently Approved ...
Edwards Lifesciences today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results